| A three-dimensional viscoelastic model for cell deformation with experimental verification H Karcher, J Lammerding, H Huang, RT Lee, RD Kamm, ... Biophysical journal 85 (5), 3336-3349, 2003 | 263 | 2003 |
| Force-induced focal adhesion translocation: effects of force amplitude and frequency PJ Mack, MR Kaazempur-Mofrad, H Karcher, RT Lee, RD Kamm American journal of physiology-Cell Physiology 287 (4), C954-C962, 2004 | 97 | 2004 |
| The “efficacy-effectiveness gap”: historical background and current conceptualization C Nordon, H Karcher, RHH Groenwold, MZ Ankarfeldt, F Pichler, ... Value in Health 19 (1), 75-81, 2016 | 93 | 2016 |
| Role of simulation in understanding biological systems MR Kaazempur-Mofrad, M Bathe, H Karcher, HF Younis, HC Seong, ... Computers & structures 81 (8-11), 715-726, 2003 | 49 | 2003 |
| Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: a network meta-analysis of progression-free survival and overall survival in second … B Amzal, S Fu, J Meng, J Lister, H Karcher PloS one 12 (9), e0184423, 2017 | 47 | 2017 |
| Exploring the molecular basis for mechanosensation, signal transduction, and cytoskeletal remodeling MRK Mofrad, NA Abdul-Rahim, H Karcher, PJ Mack, B Yap, RD Kamm Acta biomaterialia 1 (3), 281-293, 2005 | 39 | 2005 |
| Nivolumab versus cabozantinib: comparing overall survival in metastatic renal cell carcinoma W Wiecek, H Karcher PLoS One 11 (6), e0155389, 2016 | 30 | 2016 |
| From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics J Yu, H Karcher, AL Feire, PJ Lowe The AAPS journal 13 (2), 169-178, 2011 | 19 | 2011 |
| A coarse-grained model for force-induced protein deformation and kinetics H Karcher, SE Lee, MR Kaazempur-Mofrad, RD Kamm Biophysical journal 90 (8), 2686-2697, 2006 | 19 | 2006 |
| Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison C Porta, C Szczylik, R Casciano, S Fu, B Amzal, J Lister, H Karcher, ... Critical Reviews in Oncology/Hematology 139, 143-148, 2019 | 10 | 2019 |
| 4 Continuum elastic or viscoelastic models for the cell MRK Mofrad, H Karcher, RD Kamm This page intentionally left blank, 71, 2006 | 9 | 2006 |
| Proportion of women and reporting of outcomes by sex in clinical trials for Alzheimer Disease: a systematic review and meta-analysis J Martinkova, FC Quevenco, H Karcher, A Ferrari, EC Sandset, C Szoeke, ... JAMA Network Open 4 (9), e2124124-e2124124, 2021 | 6 | 2021 |
| Trial exclusion criteria and their impact on the estimation of antipsychotic drugs effect: a case study using the SOHO database C Nordon, T Bovagnet, M Belger, J Jimenez, R Olivares, ... Schizophrenia Research 193, 146-153, 2018 | 6 | 2018 |
| Ethical and social implications of using predictive modeling for Alzheimer’s disease prevention: a systematic literature review protocol Z Angehrn, C Nordon, A Turner, D Gove, H Karcher, A Keenan, ... BMJ open 9 (3), e026468, 2019 | 3 | 2019 |
| Predictive modelling for secondary prevention of Alzheimer’s Disease: Ethical concerns and social implications based on targeted, narrative literature review Z Angehrn, H Karcher, FR de Vulpillieres, C Nordon Value in Health 21, S209, 2018 | 3 | 2018 |
| Cost-effectiveness in England of Cabozantinib for patients with advanced renal cell carcinoma (ARCC) after failure of prior therapy J Lister, A Vataire, B Amzal, J Dinet, J Meng, H Karcher, S Gabriel Value in Health 20 (9), A441, 2017 | 3 | 2017 |
| Modelling decline in cognition to decline in function in Alzheimer’s disease H Karcher, M Savelieva, L Qi, N Hummel, A Caputo, V Risson, G Capkun, ... Current Alzheimer Research 17 (7), 635-657, 2020 | 2 | 2020 |
| Ethical and Social implications of using predictive modeling for Alzheimer’s disease prevention: a systematic literature review Z Angehrn, J Sostar, C Nordon, A Turner, D Gove, H Karcher, A Keenan, ... Journal of Alzheimer's Disease 76 (3), 923-940, 2020 | 2 | 2020 |
| The Comparative Cost-Effectiveness of Cabozantinib, Everolimus and Axitinib in Advanced Renal Cell Carcinoma (ARCC) After Failure of Prior Therapy: Scottish Perspective J Lister, A Vataire, B Amzal, J Dinet, J Meng, H Karcher, S Gabriel Value in Health 20 (9), A440, 2017 | 2 | 2017 |
| A model for Alzheimer’s disease in the prevention setting A Caputo, A Racine, I Paule, C Feller, M Savelieva, N Hummel, H Karcher, ... Value in Health 20 (9), A756, 2017 | 2 | 2017 |
Witold WięcekWAW / Development Innovation Lab, University of Chicago / 1Day Sooner / CertaraE-mail megerősítve itt: certara.com
